Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of the myeloid line of white blood cells and impaired production
of normal blood cells. If untreated, patients die of infection or bleeding usually in a
matter of weeks. CSL360 is a neutralising monoclonal antibody which is believed to target the
cells that are thought to drive AML but that are not effectively killed by standard
treatment. The aims of the study are to determine a biologically active dose of CSL360 and
generate understanding of a rational schedule of administration for future studies.